Why NovoCure Stock Skyrocketed This Week

Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%.

Why? The medical technology company reported solid first-quarter results. The company also provided several key updates that investors reacted positively to.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

NovoCure shared important updates

A key highlight from NovoCure's earnings call was the announcement of European CE Mark approval for OptuneLua in the treatment of metastatic non-small cell lung cancer (NSCLC). The CE Mark allows the company to market the device in Europe. OptuneLua, a medical device that emits an electric field disrupting cancer cells, uses NovoCure's core technology. The launch in Europe is an important milestone in the company's international expansion strategy and will help the company drive revenue growth.

Investors also received promising news regarding NovoCure's Phase 3 clinical trial for patients with a specific type of pancreatic cancer that is particularly hard to treat. The trial data showed a "meaningful survival benefit" and is the first to do so for this particular cancer. The results mean the company could open another major market for NovoCure's tumor treating technology.

The company's revenue growth remains solid

NovoCure reported $155 million in net revenue for Q1 2025, representing a 12% increase year over year. This growth was driven by expansion of the company's active patient base, especially in France, Japan, Germany, and the United States. As the company grows, its margins were slightly reduced, from 76% to 75% year over year. The reduction was explained, however, by a lag in reimbursement for some of its treatments.

The company is still operating at a loss, however, losing $34 million this quarter. That's not unusual for a company in NovoCure's position, however. As the company launches in Europe and continues to prove its technology is useful in more indications, its revenue could grow considerably. I think the stock is headed in the right direction and is a solid pick for those with an elevated risk tolerance.

Should you invest $1,000 in NovoCure right now?

Before you buy stock in NovoCure, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and NovoCure wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $591,533!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $652,319!*

Now, it’s worth noting Stock Advisor’s total average return is 859% — a market-crushing outperformance compared to 158% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 21, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy.